The independent financial analyst theScreener just lowered the general evaluation of CRODA INTERNATIONAL (GB), active in the Speciality Chemicals industry. As regards its fundamental valuation, the title now shows 0 out of 4 stars while market behaviour can be considered defensive. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Neutral. As of the analysis date February 23, 2021, the closing price was GBp 6,302.00 a...
US Dollar Breakdown Bullish For Risk Sentiment Global indexes including the MSCI ACWI and ACWI ex-US are following in the MSCI EM index's footsteps by breaking to new highs. This is bullish and signals a new leg higher is underway. Additionally, the US dollar is showing signs of a breakdown, something we view as a positive for global risk sentiment as long as the decline continues to be orderly. Overall our outlook remains bullish and we suggest buying any dips. · US Dollar (DXY) Brea...
In general, Croda International is in compliance with the British regulations relating to the organization and procedures of the Annual General Meeting. Under ITEM 2: The Company seeks shareholder approval of the Directors'Remuneration Policy. ECGS notes that the CEO's maximum variable remuneration (both short-term and long-term) could reach 375% under normal circumstances (450% in exceptional circumstances), which exceeds our limit of 300% of the base salary. Accordingly, we recommend...
Narrow-moat Croda reported first-half EBIT of GBP 175 million, flat over 2018 and below consensus and our expectations. The United States-China trade war was the key driver of lower demand, particularly in personal care. The outlook for second-half 2019 will not assuage any concerns. Croda is now expecting a slight improvement in performance during second-half 2019 compared with the prior year, which doesn’t tally with consensus expectations for a 10% increase in EBIT. Shares are trading down ...
Narrow-moat Croda reported first-half EBIT of GBP 175 million, flat over 2018 and below consensus and our expectations. The United States-China trade war was the key driver of lower demand, particularly in personal care. The outlook for second-half 2019 will not assuage any concerns. Croda is now expecting a slight improvement in performance during second-half 2019 compared with the prior year, which doesn’t tally with consensus expectations for a 10% increase in EBIT. Shares are trading down ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.